Table 1.
Description of the consortium data sets used for stage 1 and stage 2
| Alzheimer’s disease cases |
Controls |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Consortium | N | Percent women |
Mean AAO (s.d.) |
N | Percent women |
Mean AAE (s.d.) |
|||
| Stage 1 | ADGC | 10,273 | 59.4 | 74.7 | (7.7) | 10,892 | 58.6 | 76.3 | (8.1) |
| CHARGE | 1,315 | 63.6 | 82.7 | (6.8) | 12,968 | 57.8 | 72.8 | (8.6) | |
| EADI | 2,243 | 64.9 | 68.5 | (8.9) | 6,017 | 60.7 | 74.0 | (5.4) | |
| GERAD | 3,177 | 64.0 | 73.0 | (8.5) | 7,277 | 51.8 | 51.0 | (11.8) | |
| N | 17,008 | 37,154 | |||||||
| Country | N | Percent women |
Mean AAO (s.d.) |
N | Percent women |
Mean AAE (s.d.) |
|||
| Stage 2 | Austria | 210 | 61.0 | 72.5 | (8.1) | 829 | 43.3 | 65.5 | (8.0) |
| Belgium | 878 | 66.1 | 75.4 | (8.6) | 661 | 59.5 | 65.7 | (14.3) | |
| Finland | 422 | 68.0 | 71.4 | (6.9) | 562 | 59.3 | 69.1 | (6.2) | |
| Germany | 972 | 63.9 | 73.0 | (8.6) | 2,378 | 53.1 | 69.5 | (10.1) | |
| Greece | 256 | 63.3 | 69.2 | (8.0) | 229 | 34.1 | 49.3 | (16.4) | |
| Hungary | 125 | 68.0 | 74.9 | (6.8) | 100 | 69.0 | 74.4 | (6.5) | |
| Italy | 1,729 | 66.5 | 71.5 | (8.7) | 720 | 55.7 | 70.0 | (10.4) | |
| Spain | 2,121 | 66.3 | 75.0 | (8.3) | 1,921 | 55.3 | 70.2 | (10.8) | |
| Sweden | 797 | 61.7 | 76.8 | (8.1) | 1,506 | 62.8 | 70.6 | (8.7) | |
| UK | 490 | 57.6 | 74.6 | (8.7) | 1,066 | 29.2 | 73.8 | (6.5) | |
| United States | 572 | 61.9 | 83.5 | (7.6) | 1,340 | 54.0 | 79.3 | (6.8) | |
| N | 8,572 | 11,312 | |||||||
AAO, age at onset; AAE, age at examination.